The vaccine for HIV being developed by the Norwegian vaccine company Bionor Pharma could soon be a reality as researchers have found that median HIV viral load reduction more than doubled among participants with high anti-C5/gp41732-744 antibody levels.
Scientists have identified natural human antibodies against the virus that causes Middle East Respiratory Syndrome (MERS), a step toward developing treatments for the newly emerging and often-fatal disease.
A powerful infusion of HIV-fighting antibodies beat back a potent form of the virus in monkeys and kept it at bay for weeks, U.S. government scientists and a team led by Harvard University found, offering a potential next step in the battle against human HIV.
By screening a library of billion llama antibodies on live Ebola viruses in the Texas Biomedical Research Institute`s highest biocontainment laboratory, scientists in San Antonio have identified a potential weakness in the make-up of these deadly agents that can immediately yield a sensitive test.
Observing the evolution of a particular type of antibody in an infected HIV-1 patient has provided insights that will enable vaccination strategies that mimic the actual antibody development within the body.
A monoclonal antibody therapy developed by MassBiologics of the University of Massachusetts Medical School (UMMS) and tested in an animal model at the Texas Biomedical Research Institute, prevents infection by the hepatitis C virus (HCV).